These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 16641477)

  • 1. Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus?
    Kalil AC; Puumala S; Stoner J
    Antimicrob Agents Chemother; 2006 May; 50(5):1910; author reply 1910-1. PubMed ID: 16641477
    [No Abstract]   [Full Text] [Related]  

  • 2. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.
    Weigelt J; Itani K; Stevens D; Lau W; Dryden M; Knirsch C;
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2260-6. PubMed ID: 15917519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
    Itani KM; Weigelt J; Li JZ; Duttagupta S
    Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
    Stevens DL; Herr D; Lampiris H; Hunt JL; Batts DH; Hafkin B
    Clin Infect Dis; 2002 Jun; 34(11):1481-90. PubMed ID: 12015695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial.
    Li Z; Willke RJ; Pinto LA; Rittenhouse BE; Rybak MJ; Pleil AM; Crouch CW; Hafkin B; Glick HA
    Pharmacotherapy; 2001 Mar; 21(3):263-74. PubMed ID: 11256381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved outcomes with linezolid for methicillin-resistant Staphylococcus aureus infections: better drug or reduced vancomycin susceptibility?
    Howden BP; Charles PG; Johnson PD; Ward PB; Grayson ML
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4816; author reply 4816-7. PubMed ID: 16251343
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis.
    Itani KM; Biswas P; Reisman A; Bhattacharyya H; Baruch AM
    Clin Ther; 2012 Aug; 34(8):1667-73.e1. PubMed ID: 22770644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linezolid versus vancomycin for methicillin-resistant Staphylococcus aureus infections.
    Johnson JR
    Clin Infect Dis; 2003 Jan; 36(2):236-7. PubMed ID: 12522761
    [No Abstract]   [Full Text] [Related]  

  • 9. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
    Stein GE; Wells EM
    Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.
    Bounthavong M; Hsu DI
    Curr Med Res Opin; 2010 Feb; 26(2):407-21. PubMed ID: 20001574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Puzniak LA; Morrow LE; Huang DB; Barreto JN
    Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
    Sharpe JN; Shively EH; Polk HC
    Am J Surg; 2005 Apr; 189(4):425-8. PubMed ID: 15820454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo bioluminescence imaging to evaluate systemic and topical antibiotics against community-acquired methicillin-resistant Staphylococcus aureus-infected skin wounds in mice.
    Guo Y; Ramos RI; Cho JS; Donegan NP; Cheung AL; Miller LS
    Antimicrob Agents Chemother; 2013 Feb; 57(2):855-63. PubMed ID: 23208713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on linezolid: the first oxazolidinone antibiotic.
    Wilcox MH
    Expert Opin Pharmacother; 2005 Oct; 6(13):2315-26. PubMed ID: 16218891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linezolid use in sepsis due to methicillin-susceptible Staphylococcus aureus.
    De Gascun C; Rajan L; O'Neill E; Smyth EG
    J Antimicrob Chemother; 2006 Jan; 57(1):150-1. PubMed ID: 16244085
    [No Abstract]   [Full Text] [Related]  

  • 16. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials.
    Beibei L; Yun C; Mengli C; Nan B; Xuhong Y; Rui W
    Int J Antimicrob Agents; 2010 Jan; 35(1):3-12. PubMed ID: 19900794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus.
    Itani KM; Dryden MS; Bhattacharyya H; Kunkel MJ; Baruch AM; Weigelt JA
    Am J Surg; 2010 Jun; 199(6):804-16. PubMed ID: 20227056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter?
    Nathwani D
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii37-44. PubMed ID: 12730141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of linezolid against methicillin-resistant or vancomycin-insensitive Staphylococcus aureus in a model of hematogenous pulmonary infection.
    Yanagihara K; Kaneko Y; Sawai T; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3288-91. PubMed ID: 12234863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan.
    Kohno S; Yamaguchi K; Aikawa N; Sumiyama Y; Odagiri S; Aoki N; Niki Y; Watanabe S; Furue M; Ito T; Croos-Dabrera R; Tack KJ
    J Antimicrob Chemother; 2007 Dec; 60(6):1361-9. PubMed ID: 17913720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.